 |
His-D-Trp-Ala-Trp-D-Phe-Lys NH2 |
|---|---|
| Trade Name | |
| Orphan Indication | For the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion |
| USA Market Approval | USA |
| USA Designation Date | 1990-05-23 00:00:00 |
| Sponsor | SmithKline Beecham Pharmaceuticals;One Franklin Plaza;Philadelphia, Pennsylvania, 19101 |
